Berberine crystalline nanoparticles for respiratory health
Introducing berberine crystalline nanoparticles (BCN) aimed at enhancing solubility and bioavailability to treat respiratory disorders like asthma, COPD, and allergic rhinitis. BCN offers anti-inflammatory and anti-fibrotic benefits, with preclinical studies underway for further validation.
Overview
The innovative berberine crystalline nanoparticles (BCN) formulation offers a promising solution for treating respiratory disorders such as mild asthma, COPD, allergic rhinitis, and chronic sinusitis. Traditional therapies often provide only symptomatic relief and are limited by poor solubility and low bioavailability. BCN, developed using a scalable nanoprecipitation technique, enhances permeability and targets inflamed respiratory tissues, demonstrating significant anti-inflammatory and anti-fibrotic properties in initial studies. This approach not only alleviates symptoms but also addresses underlying disease mechanisms, representing a potentially transformative advancement in respiratory therapeutics.
Technical specifications
- Formulation: Berberine crystalline nanoparticles are created using a scalable nanoprecipitation technique.
- Key Features:
- Enhanced solubility and bioavailability of berberine.
- Targeted delivery to inflamed respiratory tissues.
- Demonstrated anti-inflammatory and anti-fibrotic properties in pilot studies.
- Research Phases:
- Phase 1: Advanced in vitro validation with cytokine profiling and co-culture models.
- Phase 2: Preclinical in vivo studies in murine models for asthma and COPD.
- Phase 3: Formulation optimization for oral and nasal delivery.
- Phase 4: Clinical trials focusing on safety and efficacy.
Technology readiness level
The BCN formulation is currently at Technology Readiness Level 4, indicating it has been validated in lab settings and is moving towards advanced preclinical evaluation. Collaborative efforts are underway to prepare for early-phase clinical trials, aiming to bring this novel solution closer to market readiness.
About University of Technology, Sydney
University of Technology Sydney (UTS) is a comprehensive public research university with a practice‑based ethos and strong industry engagement at the southern gateway of Sydney’s CBD. For corporate partners, co‑located infrastructure includes UTS Tech Lab in Botany for prototyping, testing and pilot‑scale work, the 360‑degree Data Arena for immersive visualisation, and ProtoSpace for advanced additive manufacturing; a GMP‑lite biologics facility supports training and translational bioprocessing. The city campus sits within the Tech Central innovation district, connecting companies to startups and skilled talent via co‑op and cadetship pipelines. Research is supported by competitive national funding, including the Australian Research Council and National Health and Medical Research Council. A dedicated commercialisation and IP function and the UTS Startups community help move ideas to market.
delivered to your inbox.